Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

http://www.wikidata.org/entity/Q37216476

about

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.Hypomethylating agents after allogeneic blood stem cell transplantation.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature.Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia.

P2860

Q33830964-4270CD58-C9D8-436A-B376-98616C21049F Q37531039-6B275B06-8D88-4236-B2B4-A2A25D31E485 Q37624593-4BBE8FC4-3DF6-4BBA-BB0A-FC4118012ABE Q39307476-AB3A62C9-D3A6-4C17-9CFE-4FB6AE26E51B Q40261211-FAD269E8-AE5C-41DE-BF78-EDED91E05835 Q40454294-FE71DA6A-E82A-42B1-A59D-F43EFC6B5663 Q41336256-9C19B007-DA31-48AD-BD8B-FA6403A46844 Q42344562-06E212A7-50A2-4CA1-B2D9-9E8BD8BA2AF1 Q49905502-18F1576E-5EF2-431D-A440-94989652C0F8 Q49976405-D83C09B4-068B-47C6-9974-60076D903BD3 Q55515367-409ED332-EE49-45DC-9DD7-F567B4C3B644

P2860

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

http://www.wikidata.org/entity/Q37216476

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical activity of azacitidi ...... on for acute myeloid leukemia.

@en

Clinical activity of azacitidi ...... on for acute myeloid leukemia.

@nl

type

label

Clinical activity of azacitidi ...... on for acute myeloid leukemia.

@en

Clinical activity of azacitidi ...... on for acute myeloid leukemia.

@nl

prefLabel

Clinical activity of azacitidi ...... on for acute myeloid leukemia.

@en

Clinical activity of azacitidi ...... on for acute myeloid leukemia.

@nl

P1433

Q37216476-6D64707B-DB35-4028-95CA-5B10F4304A6E

P1476

Q37216476-B5F833CE-DC01-4491-BABF-A2D1CA647AF5

P2093

Q37216476-35661A14-099C-4237-9A57-778C40460070

Q37216476-6094BC9D-2C6B-4930-865F-3B12F2B9A1DE

Q37216476-8EEC0AE6-82CF-4E75-B84A-727BE145BA13

Q37216476-AB6BAEEB-2390-4FE0-B0AF-2A34D2DF2755

Q37216476-AF1E7890-2D03-4C6D-A3C3-ACF4322EEB8E

Q37216476-B6AC7894-71B5-4F1A-B943-E66158A52483

Q37216476-CBE097A7-0BB0-44AA-81F1-A0981E7BAA83

Q37216476-CC33867C-7ACF-45CC-BC6F-0C44ACB60A01

Q37216476-D360FD95-6EE6-46C0-BE8B-F6968E83AA9D

Q37216476-E87768E8-983E-401C-9045-DA33F0671C08

P2860

Q37216476-21315A00-5709-4D84-BB3D-F945A3EF6552

Q37216476-2895D430-AC52-4DE2-AA2C-4A26A2563396

Q37216476-2BDD92DA-4309-40E7-BE9B-78F220FE3B07

Q37216476-4A107698-2955-4DF5-A7F3-C9FB149DD3C5

Q37216476-5AF67EA7-FDD5-4909-877C-44F7BC407344

Q37216476-61A23445-6F2F-4522-A197-DEA2FE98C9F8

Q37216476-6FE19B34-F4A9-4D15-8D2A-07D5DDC8B31A

Q37216476-74EB43D9-D367-4231-B80E-EB01741ADE3E

Q37216476-88619686-74C6-41E6-8406-A2F48C4E0899

Q37216476-B437C2C9-4206-4F8E-8ECE-3ACF2E4147B0

P304

Q37216476-311A21AE-3056-4F7F-8A2B-63A8BAAB5681

P31

Q37216476-0EFF3CDE-AC9B-4ECF-877A-2A149931D5B9

P356

Q37216476-B3A32034-DC17-44F8-8DC1-D9EFCC7F49BF

P433

Q37216476-50FE5E5B-9C56-418D-AEA4-B9D0A78D4FDE

P478

Q37216476-34BABFB1-DA62-4347-9016-00E80B45DAB4

P50

Q37216476-6349E98C-7C4B-4EA0-8188-24AC12DDC779

Q37216476-C2931B10-2A07-4DA3-8F6A-9D1D5924462A

Q37216476-D084B26C-BABD-4DBB-A17B-01ED85077ECF

P577

Q37216476-26D7450F-F3C4-4265-8562-E828DDB4CC16

P698

Q37216476-2E98A6BB-F2FC-4207-85BB-29FF68606435

P921

Q37216476-47A1D12F-6A31-42AC-B5A0-D4BE16E117D5

P932

Q37216476-56BC7965-090A-495F-9563-43813C5746FC

P356

HAEMATOL.2015.140996

P1433

P1476

Clinical activity of azacitidi ...... ion for acute myeloid leukemia

@en

P2093

Arnon Nagler

http://www.w3.org/2001/XMLSchema#string

Didier Blaise

http://www.w3.org/2001/XMLSchema#string

Jean Henri Bourhis

http://www.w3.org/2001/XMLSchema#string

Juergen Finke

http://www.w3.org/2001/XMLSchema#string

Marie Robin

http://www.w3.org/2001/XMLSchema#string

Michael Hallek

http://www.w3.org/2001/XMLSchema#string

Mohamad Mohty

http://www.w3.org/2001/XMLSchema#string

Myriam Labopin

http://www.w3.org/2001/XMLSchema#string

Nicolaus Kröger

http://www.w3.org/2001/XMLSchema#string

Patrice Chevallier

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Defining the intensity of conditioning regimens: working definitions

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retros

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Optimising the conditioning regimen for acute myeloid leukaemia.

P304

879-883

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2015.140996

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Ibrahim Yakoub-Agha

Charles Craddock

Henrik Sengeløv

P577

2016-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27081178

http://www.w3.org/2001/XMLSchema#string

P921

P932

5004468

http://www.w3.org/2001/XMLSchema#string